99 results about "Drug transport" patented technology

A system for monitoring medication compliance in a patient includes an electronic pill that includes a drug-transporting device and an antenna positioned on a surface of the drug-transporting device. A detector is positionable external a gastrointestinal tract of a patient for detecting a presence of the antenna in the patient gastrointestinal tract.

A system for monitoring medication compliance in a patient includes an electronic pill that includes a drug-transporting device and an antenna positioned on a surface of the drug-transporting device. A detector is positionable external a gastrointestinal tract of a patient for detecting a presence of the antenna in the patient gastrointestinal tract.

Methods and systems for treating patients suffering from eating disorders, e.g. obesity, through the dispensation of a drug by an implantable infusion pump (IIP) delivering drug into the cerebral spinal fluid (CSF) at a site of the intrathecal space in amounts and at times effective to suppress the patient's appetite through interaction of the drug transported through the CSF with receptors in the brain. Delivery of a programmed drug dosage is preferably by one of time-out of programmed time(s) of day, a command received from the patient, or a trigger signal developed from a sensed GI tract signal accompanying peristalsis.

The invention discloses a caco-2 cell model for CRISPR / CAS9-mediated drug transporter targeted knockout and a method thereof. The method is used for non-diagnostic or therapeutic purposes and comprises the following steps: designing sgRNA with target specificity for P-gp, BCRP and MRP2 transporters and constructing a sgRNA expression vector, wherein a sequence of the designed sgRNA is shown as SEQID NO. 1-6 in a sequence table; respectively designing P-gp, BCRP and MRP gene single knockout and pairwise combination double knockout by utilizing CRISPR / CAS9, co-transfecting a caco-2 cell with anhCas9 plasmid and performing monoclonal expansion culture to obtain the caco-2 cell model for transporter gene targeting. The caco-2 cell model obtained by the method disclosed by the invention has the beneficial effects that the mutual interference among different transporters is effectively eliminated, and a more specific and more sensitive cell model is provided for drug transport research.

The invention discloses a method for synthesis of a double-casing layer carbon nanometer hollow polyhedron by a metal-organic framework as a template and belongs to the field of novel energy and novel materials. The method comprises that a zeolitic imidazolate framework with a core-shell nanometer structure as a structure precursor is calcined at a high temperature to form the double-casing layer nanometer carbon hollow polyhedron. The cheap and easily available zeolitic imidazolate framework as a structure precursor is used for preparation of the double-casing layer carbon nanometer hollow polyhedron. The method has simple processes, is free of a template, realizes precise control of a shell structure by change of a zinc / cobalt-based zeolitic imidazolate framework ratio or calcining conditions, is environmentally friendly and can be industrialized easily. The double-casing layer carbon nanometer hollow polyhedron has a wide application prospect in the fields of energy storage, catalysis, photoelectric materials and drug transport.

A membrane receptor reagent and assay is disclosed in which liposomes are bound to an evanescent wave emitting surface. Membrane receptors on the liposome's fluid lipid bilayer membrane are labeled with a fluorescent or luminescent moiety. These membrane receptors are free to diffuse randomly throughout the liposome surface, and thus tend to redistribute according to externally applied forces. The evanescent wave-emitting surface additionally contains reagents that reversibly bind to the membrane receptors, tending to bring them closer to region of high evanescent wave intensity. Test analytes that disrupt or promote the association between the membrane receptors and the surface reagents act to change the average distance between the membrane receptors and the evanescent wave emitting surface, resulting in a change in the fluorescent or luminescent signal. This reagent and assay system functions with physiologically important membrane receptors such as GPCR receptors, other 7-tm receptors, drug transport proteins, cytochrome P450 membrane proteins and other clinically important membrane components. The reagent and assay methods may be incorporated into microarrays, capillaries, flow cells and other devices, and used for drug discovery, ADMET, and other biomedically important assays.

The invention discloses a targeted polypeptide capable of being specifically combined with tumors, particularly a targeted peptide capable of being specifically combined with liver cancer tissues and application thereof in diagnosis and treatment of liver cancer. The liver cancer targeted peptide is preferably HCC-47 of which the amino acid sequence is SQDIRTWNGTRS; and the liver cancer targeted peptide is specifically combined with the liver cancer tissues, and can not be specifically combined with cervical carcinoma cells Hela, mammary cancer cells MDA-MB231, kidney cancer cells CRL-1932 and lung cancer cells A549. The polypeptide is obtained by in-vitro biological elutriation by combining a bacteriophage display library and a living body cross sectioning technique. The polypeptide can be used in a molecular imaging preparation for early diagnosis of liver cancer. The polypeptide can also be used in targeted modification and preparation of drugs for treating liver cancer. The polypeptide can also be used for targeted modification on drug transport carriers, thereby providing a new way for diagnosing or treating patients with liver cancer.

The invention discloses a metal oxide hollow nanometer particle-embedded nitrogen-doped nanometer foamy carbon synthesis method and belongs to the field of novel energy and novel materials. The synthesis method comprises that through high temperature calcining and low temperature oxidation, the metal oxide hollow nanometer particle-embedded nitrogen-doped nanometer foamy carbon is prepared from metal nitrates as metal oxide precursors and foaming agents, and a nitrogen-containing organic molecule as a carbon source and nitrogen source precursor. The synthesis method utilizes the cheap and easily available organic polymer and a plurality of common metal nitrates as precursors to prepare the metal oxide hollow nanometer particle-embedded nitrogen-doped nanometer foamy carbon. The synthesis method has simple processes, is free of a template, realizes accurate adjustment and control of the foamy carbon structure by change of a metal salt / polyvinylpyrrolidone ratio or calcining conditions, is environmentally friendly and can be industrialized easily. The metal oxide hollow nanometer particle-embedded nitrogen-doped nanometer foamy carbon has a wide application prospect in the fields of energy storage, catalysis, photoelectric materials and drug transport.

The invention relates to a preparation method of in-situ gel based on magnetic graphene oxide and application thereof and effectively solves a problem of the application of the magnetic graphene oxide in-situ gel as a magnetic thermal-therapy medium and a drug transport carrier in treatment of tumors. In the preparation method, the in-situ gel based on the magnetic graphene oxide, as a drug carrier system, is prepared by mixing the magnetic graphene oxide on which a drug is carried with a chitosan / [beta]-sodium glycerophosphate gel, wherein the volume ratio of the magnetic graphene oxide on which the drug is carried to the chitosan / [beta]-sodium glycerophosphate gel is 1-3:1. On the originally basis that the graphene oxide supports an iron oxide, by means of a condensation reaction, a macromolecular polymer, polyethyleneimine, which is strong in reaction activity, is connected to the surface of the graphene oxide to generate a water-soluble magnetic carrier, and finally the carrier is mixed with the chitosan in-situ gel to prepare the magnetic graphene oxide in-situ gel. The raw materials are wide in sources. The in-situ gel based on the magnetic graphene oxide is low in cost, is good in quality, is strong in targeting, is good in use effect and is a great creative achievement on tumor treatment drugs.

The invention provides a rapid, quantitative assay to directly assess the impact of a diverse range of sugars upon the sugar-mediated uptake of corresponding sugar-conjugates into various cell types.

The invention belongs to the field of biomedicine and relates to a human original cell permeable peptide hPP3 and usage thereof. The cell permeable peptide hPP3 provided by the invention has a cell membrane permeation function, thereby being capable of carrying such large molecules as protein to enter a plurality kind of cells in a transmembrane manner; since the peptide segment is derived from human protein, the possibility of causing human body immune response is small, the potential insecurity factors are relatively small, so that the hPP3 can serve as a transmembrane transport carrier having brilliant development prospect of such bioactive molecules as protein, polypeptide, and the hPP3 can be used as an intracellular drug transport carrier.

A method and medical device for generating transient bubbles is provided. Fluid is delivered under pressure through bubble generating means and thereby transient bubbles are generated. The bubbles are micro or nano sized. An ultrasonic source may be used to further vibrate the bubble generating means so as to adjust the size and size consistency of the bubbles. Infusion means may also be provided for infusing the bubbles in a patient. A therapeutic agent, in the form of or delivered in combination with, bubbles may be injected at the point of interest. An ultrasound pulse may additionally be provided to activate bubbles to enhance drug transport through tissues and across cell membranes. The device provides a means to locally generate transient bubbles, to facilitate acoustical activation of therapeutic agents, and the acoustic activation of bubbles infused within therapeutic agents, in order to enhance treatment efficacy.

The invention discloses an anti-tumor controlled release nanocomposite and a preparation method thereof. The nanocomposite utilizes nano diamonds after carboxylation treatment as carriers, and comprises adsorption enzyme self degradation chains and cell-penetrating peptides. The preparation method is implemented as follows: dispersing nano diamonds after carboxylation treatment of a strong acid in a dimethyl sulfoxide aqueous solution, adding an anti-tumor drug connected with a self degradation chain, and stirring under room temperature to obtain a composite; and dispersing the obtained composite in water, adding the cell-penetrating peptides, and stirring and drying at room temperature to obtain the anti-tumor controlled release nanocomposite. The nano carrier composite in the invention is simple and convenient in preparation, has no toxicity and pollution, and is easy for industrialization. In vitro research shows that the composite can realize controlled release of an anti-tumor drug, enhance the killing effect of the drug on tumors, and provide a new material and method for drug transport.

On each of a plurality of disposed racks, an injection drug storing container is each detachably mounted. The injection drug storing container includes a transportation device for transporting a stored injection drug in one direction. The injection drug transported by the transportation device is housed in each housing portion formed on a circumferential portion of a rotating body one by one. The injection drug in each housing portion is sequentially delivered one by one by rotation of the rotating body.

The invention discloses preparation and application of PEG / Dex dual-aqueous-phase based calcium carbonate / calcium alginate composite microcapsules. The composite microcapsules are produced by taking dual-aqueous-phase (glucan / polyethylene glycol) liquid droplets as a template. The composite microcapsules are good in monodispersity, and the particle size can be accurately regulated and controlled from several microns to several millimeters. The microcapsules are of hollow structures, capsule walls are of double layers, the thickness of the capsule walls is controllable (about 1 / 50 to 1 / 4 the particle size of the microcapsules), inner sides of the capsules are of dense calcium carbonate layers, and outer sides of the capsules are of calcium alginate layers. Compared with pure calcium alginate microcapsules, the microcapsules have good mechanical strength and a dense capsule wall structure, the damage to capsule layers caused by a shearing force is avoided, and the leakage of contents isinhibited. The microcapsules can be used for constructing a low-leakage drug transport system and can also be used for preparing an immobilized enzyme carrier, which is high in number of times of recycle, long in preservation time and difficult in swelling. According to the preparation and the application, the application of calcium alginate microcapsules in the fields of biomedicines, food industry, chemical industry for daily use, enzyme engineering and the like is extended.

It is intended to provide a screening system for a centrally acting drug transported across the blood-brain barrier, a drug acting on the blood-brain barrier itself, or a drug transferred into the brain without being expected to centrally act. Moreover, another object of the present invention is to achieve pathogenesis analysis study or the screening in a diseased state by applying various diseased environments to this screening system. The present invention provides an in-vitro model of blood-brain barrier obtained by using a three-dimensional culture apparatus comprising: a culture solution; a plate holding the culture solution; and a filter immersed in the culture solution and placed in no contact with the inside bottom of the plate, the filter having plural pores of 0.35 to 0.45 μm in diameter, and by comprising: seeding primary cultured brain capillary endothelial cells onto the upper surface of the filter; seeding primary cultured brain pericytes onto the under surface of the filter; seeding primary cultured astrocytes onto the inside surface of the plate; and coculturing these cells in a normal culture solution.

The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the Slc7a11 (NC_005101.2) gene, the Abcb1 (NC_005103.2) gene, etc. The present invention also provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene.

The invention relates to a preparation method of temperature-sensitive hydrogel based on functionalized graphene oxide and an application thereof and effectively solves a problem of the preparation of the functionalized graphene oxide temperature-sensitive hydrogel and the application of the functionalized graphene oxide temperature-sensitive hydrogel as a thermal-therapy medium and a drug transport carrier in preparation of a tumor treatment photo-thermal targeted drug. In the method, the temperature-sensitive hydrogel based on the functionalized graphene oxide is prepared by mixing the functionalized graphene oxide on which a drug is carried with poloxamer P407 / P188 gel, wherein the volume ratio of the functionalized graphene oxide on which the anti-tumor drug is carried to the poloxamer P407 / P188 gel is 1-3:1. Water-soluble macromolecular chitosan being strong in reaction activity is connected to the surface of the original graphene oxide to form a water-soluble functionalized carrier, wherein the functionalized carrier is mixed with chitosan temperature-sensitive hydrogel to obtain the temperature-sensitive hydrogel based on the functionalized graphene oxide. The raw materials are wide in sources. The temperature-sensitive hydrogel is abundant in raw materials, is low in cost, is good in effect, can increase the concentration of the carried drug at the position of tumors, and is a great creative achievement on tumor treatment drugs.

The invention relates to the preparation of a magnetic nano-drug carrier and a method for using the magnetic nano-drug carrier to load doxorubicin hydrochloride, belonging to the technical field of magnetic nano-material drug transport. The invention mainly aims at solving the technical problems of high toxicity and poor treatment effect of the prior art. According to a technical scheme, a preparation method of the magnetic nano-drug carrier comprises the following steps: (1) preparing a cyclodextrin-hyaluronic acid supermolecule polymer; (2) preparing magnetic graphene oxide; (3) preparing the cyclodextrin-hyaluronic acid polymer-functionalized magnetic magnetic nano-drug carrier. Compared with the prior art, the magnetic nano-drug carrier is high in biocompatibility and low in toxicity,and has the characteristics of cancer cell targeted localization and drug controlled release, thus having an important application value in the aspect of biological drug carriers.

The invention relates to diamond-shaped dodecahedron hollow potassium tannate nanoparticles and a preparation method thereof which are characterized in that obtained potassium tannate nanoparticles have diamond-shaped dodecahedron hollow appearance structures and are directly prepared in an aqueous solution based on an acid-base neutralization principle and a dissolution mechanism in a ZIF-8 acid environment under the condition of a room temperature. The preparation method comprises the following preparation steps: (1) firstly preparing a ZIF-8 nanoparticle colloidal solution in an ethylene glycol solution by taking zinc nitrate and 2-methylimidazole as raw materials, centrifugally separating, performing ultrasonic cleaning with alcohol and then dispersing in the aqueous solution; (2) adding potassium hydroxide and a tannic acid aqueous solution into the ZIF-8 aqueous solution under the condition of rapid stirring, uniformly mixing and reacting for 10-60 minutes under stirring at a room temperature; (3) centrifugally separating the prepared colloidal solution obtained in the step (2) at a high speed and performing ultrasonic cleaning to obtain the diamond-shaped dodecahedron hollow potassium tannate nanoparticles. The hollow potassium tannate nanoparticles obtained by the preparation method provided by the invention have important application values in drug transport, UV protection, bacterium resistance, pollutant adsorption and the like.

The invention relates to injectable hydrogel with self-healing and pH response properties, and a preparation method and an application thereof. The preparation method comprises the following steps: using a water soluble polymer CEC as a main raw material of the hydrogel; using a PEGDA polymer as a crosslinking agent; and mixing a CEC polymer solution with a PEGDA polymer solution, and performing mutual crosslinking to obtain the injectable hydrogel with self-healing and pH response properties. The preparation method is simple, no additional chemical reagent is added in the preparation process, no purification is carried out, the injectable hydrogel is safe and nontoxic, meanwhile the operation is convenient, and the raw material cost is low; and the prepared hydrogel CEC / PEGDA has excellent self-healing property, and obvious pH response property when serving as a drug carrier, can greatly promote the adhesion and proliferation of fibrocyte (L929), displays very strong biocompatibility, and has a very good application prospect in the field of drug transport.

The invention belongs to the field of medicines for treating cancer, and in particular relates to a method for reversing drug resistance of breast cancer by using miR-487a. The method comprises the following steps: (1) inhibiting BCRP (Breast Cancer Resistance Protein) expression and drug transport function in drug resisting cells MCF-7 / MX of breast cancer by means of a stimulant miR-487amimic of miR-487a, and increasing sensitivity to a BCRP transfer substrate mitoxantrone hydrochloride; (2) performing targeted inhibition on BCRP expression in transplantation tumor of nude mouse with breast cancer induced by MCF-7 / MX by means of a stimulant miR-487aagmir liposome, and increasing sensitivity to MX by in vivo cancer cells; and (3) up-regulating BCRP expression and drug transport function of drug susceptible cells MCF-7 by means of an inhibitor miR-487ainhibitor of miR-487a, and increasing the drug resistance to MX. The method is used for reversing drug resistance of breast cancer by using miR-487a.

The invention provides a wireless passive drug targeting administration device, and belongs to medical equipment. The device comprises a shell. The device is characterized in that a top cover is disposed on the top of the shell, and a drug storage chamber is arranged in an inner cavity of the shell; a magnetostrictive bar, a guide rod and a catheter are arranged in the drug storage chamber; the top cover is connected with one end of the guide rod, and the other end of the guide rod is arranged in the catheter; the catheter is connected with a bottom plate of the drug storage chamber, and crawling feet made of magnetostrictive materials are disposed on the lower side of the shell. An adjustable constant or alternating current source is adopted, a drug transport car is placed in a helmholtz coil, and alternating current and direct-current bias can be provided. By adjusting the magnitude of constant current and the frequency and the direction of the alternating current, the frequency and the amplitude of a magnetostrictor are adjusted, and the function of targeting administration is achieved. Besides, the release process of drugs carried on the drug transport car can be manually controlled. The dosage of the carried drugs can be increased to the largest extent under the condition that drug properties of the carried drugs are not damaged, and the drug transport car has no energy source itself.

The present invention relates to a polypeptide which excretes drugs such as cancer chemotherapeutic agents from a cell and to a gene coding therefor. More specifically, the present invention relates to a method for predicting a drug transport capability of a mammalian cell by determining a single nucleotide polymorphism(s) of ABCG2 gene and / or an amino acid polymorphism(s) of ABCG2 polypeptide and also to a polynucleotide, polypeptide, kit, and the like used for the method.

This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an mdr1 truncation.

This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an mdr1 truncation.

The invention relates to a method for detection of P-glycoprotein (P-gp) mediated rhodamine 123 (Rh123) transport in a 3D type organ and an application thereof in screening of P-gp inhibitors. The method comprises the steps: firstly, sorting small intestinal crypts of C57BL / 6 mice, inoculating a petri dish containing a matrix gel, culturing in an Advanced DMEM / F12 culture medium, and forming the 3D type organ; and then carrying out qualitative and quantitative detection of P-gp mediated Rh123 transport and influence of the P-gp inhibitor verapamil on Rh123 transport by using the 3D type organ model. The method particularly comprises the steps of respectively co-incubating the 3D type organ with (1) the P-gp substrate Rh123 and with (2) the Rh123 and the verapamil, releasing the Rh123 in the 3D type organ by using an ultrasonic crushing method, and finally detecting the concentration of the Rh123 on a multifunctional microplate reader. The method has the advantages of being simple, rapid, and high in sensitivity, can be combined with the 3D type organ model for carrying out research of the P-gp mediated drug transport, and also can perform research of in-vitro screening of the P-gp inhibitors.